Brian Y. Feng

ORCID: 0000-0002-4208-8624
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Innovative Microfluidic and Catalytic Techniques Innovation
  • Computational Drug Discovery Methods
  • Antibiotic Resistance in Bacteria
  • Bacterial Genetics and Biotechnology
  • Click Chemistry and Applications
  • Analytical Chemistry and Chromatography
  • Biosimilars and Bioanalytical Methods
  • Antibiotics Pharmacokinetics and Efficacy
  • Biotin and Related Studies
  • Neurological diseases and metabolism
  • Cell Image Analysis Techniques
  • Advanced biosensing and bioanalysis techniques
  • Biochemical and Structural Characterization
  • HIV/AIDS drug development and treatment
  • Drug Transport and Resistance Mechanisms
  • Biochemical and Molecular Research
  • Advanced Biosensing Techniques and Applications
  • Phytochemistry and Bioactivity Studies
  • Trace Elements in Health
  • Cellular transport and secretion
  • Bacteriophages and microbial interactions
  • Protein purification and stability
  • Synthesis and Catalytic Reactions
  • Metabolomics and Mass Spectrometry Studies
  • Alzheimer's disease research and treatments

University of Illinois Chicago
2025

University of California, Merced
2024

Enzo Life Sciences (United States)
2024

Novartis (United States)
2017-2022

Novartis Institutes for BioMedical Research
2019

Novartis (Switzerland)
2019

Novartis (Ireland)
2019

University of California, San Francisco
2003-2008

National Human Genome Research Institute
2007-2008

National Institutes of Health
2007-2008

Promiscuous small molecules plague screening libraries and hit lists. Previous work has found that several nonspecific compounds form submicrometer aggregates, it been suggested this aggregate species is responsible for the inhibition of many different enzymes. It not understood how aggregates inhibit their targets. To address question, biophysical, kinetic, microscopy methods were used to study interaction promiscuous, aggregate-forming inhibitors with model proteins. By use centrifugation...

10.1021/jm030266r article EN Journal of Medicinal Chemistry 2003-08-22

High-throughput screening (HTS) is the primary technique for new lead identification in drug discovery and chemical biology. Unfortunately, it susceptible to false-positive hits. One common mechanism such false-positives congregation of organic molecules into colloidal aggregates, which nonspecifically inhibit enzymes. To both evaluate feasibility large-scale aggregate-based inhibition quantify its prevalence among hits, we tested 70,563 from National Institutes Health Chemical Genomics...

10.1021/jm061317y article EN Journal of Medicinal Chemistry 2007-04-21

High-throughput screening (HTS) is widely used in drug discovery. Especially for screens of unbiased libraries, false positives can dominate "hit lists"; their origins are much debated. Here we determine the mechanism every active hit from a screen 70,563 molecules against β-lactamase using quantitative HTS (qHTS). Of 1274 initial inhibitors, 95% were detergent-sensitive and classified as aggregators. Among 70 remaining 25 potent, covalent-acting β-lactams. Mass spectra, counter-screens,...

10.1021/jm701500e article EN Journal of Medicinal Chemistry 2008-03-12

The Hedgehog (Hh) pathway is essential for vertebrate embryogenesis, and excessive Hh target gene activation can cause cancer in humans. Here we show that Neuropilin 1 (Nrp1) Nrp2, transmembrane proteins with roles axon guidance vascular endothelial growth factor (VEGF) signaling, are important positive regulators of signal transduction. Nrps expressed at times locations active transduction during mouse development. Using cell lines lacking key components, mediate between activated...

10.1101/gad.173054.111 article EN Genes & Development 2011-11-03

Secretory phospholipase A2 (sPLA2), an enzyme overexpressed in numerous diseases, has been used to trigger structural transformations lipid-based drug delivery systems, enabling payload release at target sites. Zwitterionic peptides are known for their superior antifouling properties, often outperforming poly(ethylene glycol) (PEG) surface modification by resisting protein adsorption. In this study, we examined lipid monolayers the water–vapor interface on a Langmuir trough, incorporating...

10.1021/acs.langmuir.4c04426 article EN Langmuir 2025-02-02

Objectives/Goals: Our aim was to identify how the epithelial–mesenchymal transition shields heterogeneous breast tumors against immune attack. Additionally, we endeavored understand whether our findings were conserved in canine mammary as a translational model for human tumors. Methods/Study Population: To interactions between quasi-mesenchymal (qM) tumor cells, epithelial (E) and cells within tumors, utilized preclinical mouse established lab. In this system, can precisely control...

10.1017/cts.2024.1023 article EN cc-by-nc-nd Journal of Clinical and Translational Science 2025-03-26

Screening in mixtures is a common approach for increasing the efficiency of high-throughput screening. Here we investigate how "compound load" influences promiscuous aggregate-based inhibition. We screened 764 molecules individually and 10 at 5 μM each, comparing observed inhibition to that predicted from single-compound results. Synergistic effects on aggregation predominated, although antagonism was also observed. These results suggest screening can increase aggregation-based nonadditive manner.

10.1021/jm060029z article EN Journal of Medicinal Chemistry 2006-03-09

In the preceding manuscript [Moreau et al. 2018, 10.1021/acs.jmedchem.7b01691] we described a successful fragment-based lead discovery (FBLD) strategy for of bacterial phosphopantetheine adenylyltransferase inhibitors (PPAT, CoaD). Following several rounds optimization two promising compounds were identified: triazolopyrimidinone 3 and 4-azabenzimidazole 4. Here disclose our efforts to further optimize these leads on-target potency Gram-negative cellular activity. Enabled by robust X-ray...

10.1021/acs.jmedchem.7b01861 article EN Journal of Medicinal Chemistry 2018-03-18

The discovery and development of new antibiotics capable curing infections due to multidrug-resistant pandrug-resistant Gram-negative bacteria are a major challenge with fundamental importance our global healthcare system. Part broad program at Novartis address this urgent, unmet need includes the search for agents that inhibit novel bacterial targets. Here we report hit-to-lead optimization inhibitors phosphopantetheine adenylyltransferase (PPAT) from bacteria. Utilizing fragment-based...

10.1021/acs.jmedchem.7b01691 article EN Journal of Medicinal Chemistry 2018-03-02

Beta-lactams comprise one of the earliest classes antibiotic therapies. These molecules covalently inhibit enzymes from family penicillin-binding proteins (PBPs), which are essential in construction bacterial cell wall. As a result, beta-lactams cause striking changes to cellular morphology, nature varies by range PBPs simultaneously engaged cell. The traditional method exploring beta-lactam polyspecificity is gel-based binding assay low-throughput and typically run ex situ extracts. Here,...

10.1021/acschembio.9b00141 article EN ACS Chemical Biology 2019-06-11

The Gram-negative cell envelope presents a formidable barrier to xenobiotics, and achieving sufficient compound exposure inside the is key challenge for discovery of new antibiotics. To provide insight on molecular determinants governing in bacteria, we developed methodology leveraging cyclooctyne-based bioorthogonal probe assess compartment-specific exposure. This can be selectively localized periplasmic or cytoplasmic compartments bacteria. Once localized, used test azide-containing...

10.1021/acsinfecdis.8b00093 article EN publisher-specific-oa ACS Infectious Diseases 2018-05-30

Drug-resistant Gram-negative bacteria are of increasing concern worldwide. Novel antibiotics needed, but their development is complicated by the requirement to simultaneously optimize molecules for target affinity and cellular potency, which can result in divergent structure-activity relationships (SARs). These challenges were exemplified during our attempts inhibitors bacterial enzyme CoaD originally identified through a biochemical screen. To facilitate lead optimization, we developed mass...

10.1021/acsinfecdis.7b00214 article EN ACS Infectious Diseases 2017-12-15

Compartmentalization is a crucial facet of many biological systems, and key aspects cellular processes rely on spatial segregation within the cell. While drug targets reside in specific intracellular compartments, tools available for assessing compound exposure are generally limited to whole-cell measurements. To address this gap, we recently developed bioorthogonal chemistry-based method assess compartment-specific demonstrated its use Gram-negative bacteria. expand applicability approach,...

10.1021/acschembio.9b00008 article EN ACS Chemical Biology 2019-03-25

Combination therapies are common in many therapeutic contexts, including infectious diseases and cancer. A approach for evaluating combinations vitro is to assess effects on cell growth as synergistic, antagonistic, or neutral using "checkerboard" experiments systematically sample of agents multiple doses. To further understand the antibiotic combinations, we employed high-content imaging study morphological changes caused by combination treatments checkerboard experiments. Using an...

10.1021/acsinfecdis.1c00312 article EN cc-by-nc-nd ACS Infectious Diseases 2021-12-23

Lipopolysacharride (LPS) forms the outer leaflet of membrane in Gram-negative bacteria and contributes to permeability barrier immune response. In this study, we established a method for monitoring LPS biosynthetic intermediates Raetz pathway (lpxA-lpxK) Escherichia coli. Metabolites from compound-treated cells genetically-perturbed were extracted whole concentrated by mixed-mode weak anion exchange (WAX) solid-phase extraction (SPE) prior analysis normal phase (NP)LC-MS/MS. Data was...

10.1371/journal.pone.0211803 article EN cc-by PLoS ONE 2019-02-08

<title>Abstract</title> The discovery of bifunctional degradation activating compounds (BiDACs) has led to the development a new class drugs that promote clearance their protein targets. BiDAC-induced ubiquitination is generally believed direct cytosolic and nuclear proteins proteolytic destruction by proteasomes. However, pathways govern other classes BiDAC targets, such as integral membrane intraorganellar proteins, have not been investigated in depth. In this study we used morphological...

10.21203/rs.3.rs-4438596/v1 preprint EN cc-by Research Square (Research Square) 2024-06-03

ADVERTISEMENT RETURN TO ISSUEPREVAddition/CorrectionNEXTSynergy and Antagonism of Promiscuous Inhibition in Multiple-Compound MixturesBrian Y. Feng Brian K. ShoichetCite this: J. Med. Chem. 2007, 50, 12, 2930Publication Date (Web):May 18, 2007Publication History Published online18 May 2007Published inissue 1 June 2007https://pubs.acs.org/doi/10.1021/jm0703439https://doi.org/10.1021/jm0703439correctionACS PublicationsCopyright © 2007 American Chemical Society. This publication is available...

10.1021/jm0703439 article EN Journal of Medicinal Chemistry 2007-05-18

Abstract Beta-lactam antibiotics comprise one of the earliest known classes antibiotic therapies. These molsecules covalently inhibit enzymes from family penicillin-binding proteins, which are essential to construction bacterial cell wall. As a result, beta-lactams have long been cause striking changes cellular morphology. The exact nature tend vary by precise PBPs engaged in since exhibit range PBP enzyme specificity. traditional method for exploring beta-lactam polyspecificity is gel-based...

10.1101/545335 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2019-02-08
Coming Soon ...